Antihypertensive therapy versus alternative therapeutic options for prehypertension: An evidence-based approach

Future Cardiology

Volumn 8, Issue 1, 2012, Pages 115-122

  Gaddam, Krishna K ^a   Ventura, Hector ^a   Lavie, Carl J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

antihypertensive therapy; cardiovascular diseases; diabetes; heart failure; hypertension; lifestyle modifications; prehypertension; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; POTASSIUM; RAMIPRIL;

AGE; ANTIHYPERTENSIVE THERAPY; ATHEROMA; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DASH DIET; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; EVIDENCE BASED MEDICINE; EXERCISE; FOLLOW UP; FRUIT; GLUCOSE TOLERANCE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HIGH POTASSIUM INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW FAT DIET; MICROALBUMINURIA; POSTMENOPAUSE; PREHYPERTENSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SODIUM RESTRICTION; STROKE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VEGETABLE; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; DIET; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; NUTRITIONAL STATUS; PREHYPERTENSION; PRIMARY PREVENTION; RISK FACTORS; SYSTOLE; UNITED STATES;

EID: 84555190774     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.83     Document Type: Review

References (46)

1. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289(19), 2560-2572 (2003). (Pubitemid 37430158)
2. Lewington S, Clarke R, Qizilbash N et al. Age specifc relevance of usual blood pressure to vascular mortality: a meta-ana lysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002). (Pubitemid 35472129)
3. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121(7), 948-954 (2010).
4. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 17(1), 22-27 (1991).
5. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358(9294), 1682-1686 (2001). (Pubitemid 33124327)
6. Jimenez-Corona A, Lopez-Ridaura R, Stern MP, Gonzalez-Villalpando C. Risk of progression to hypertension in a low-income Mexican population with prehypertension and normal blood pressure. Am. J. Hypertens. 20(9), 929-936 (2007). (Pubitemid 47313621)
7. Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch. Intern. Med. 164(19), 2113-2118 (2004). (Pubitemid 39410799)
8. Hsia J, Margolis KL, Eaton CB et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 115(7), 855-860 (2007). (Pubitemid 46294726)
9. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345(18), 1291-1297 (2001).
10. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke 36(9), 1859-1863 (2005). (Pubitemid 41266514)
11. Lee M, Saver JL, Chang B, Chang KH, Hao Q, Ovbiagele B. Presence of baseline prehypertension and risk of incident stroke. Neurology 77(14), 1330-1337 (2011).
12. Butler J, Kalogeropoulos AP, Georgiopoulou VV et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 97(16), 1304-1311 (2011).
13. Zhang Y, Lee ET, Devereux RB et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 47(3), 410-414 (2006). (Pubitemid 43740283)
14. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J. Clin. Hypertens. 6(10), 562-568 (2004).
15. Lavie CJ, Church TS, Milani RV, Earnest CP. Impact of physical activity, cardiorespiratory ftness, and exercise training on markers of infammation. J. Cardiopulm. Rehabil. Prev. 31(3), 137-145 (2011).
16. Lavie CJ, Milani RV, Verma A, O'Keefe JH. C-reactive protein and cardiovascular diseases-is it ready for primetime? Am. J. Med. Sci. 338(6), 486-492 (2009).
17. Whelton PK, He J, Appel LJ et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 288(15), 1882-1888 (2002). (Pubitemid 35168144)
18. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch. Intern. Med. 157(6), 657-667 (1997).
19. Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 336(16), 1117-1124 (1997).
20. Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 344(1), 3-10 (2001). (Pubitemid 32064838)
21. Elmer PJ, Obarzanek E, Vollmer WM et al. Effects of comprehensive lifestyle modifcation on diet, weight, physical ftness, and blood pressure control: 18-month results of a randomized trial. Ann. Intern. Med. 144(7), 485-495 (2006). (Pubitemid 46780671)
22. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation 119(15), 2026-2031 (2009).
23. Appel LJ, Sacks FM, Carey VJ et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 294(19), 2455-2464 (2005). (Pubitemid 41627923)
24. Whelton PK, He J, Cutler JA et al. Effects of oral potassium on blood pressure. Metaana lysis of randomized controlled clinical trials. JAMA 277(20), 1624-1632 (1997). (Pubitemid 27231195)
25. Chobanian AV. Prehypertension revisited. Hypertension 48(5), 812-814 (2006). (Pubitemid 44610983)
26. Staessen JA, Richart T, Wang Z, Thijs L. Implications of recently published trials of blood pressure-l owe ring drugs in hypertensive or high-risk patients. Hypertension 55(4), 819-831 (2010).
27. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354(16), 1685-1697 (2006).
28. Schunkert H. Pharmacotherapy for prehypertension-mission accomplished? N. Engl. J. Med. 354(16), 1742-1744 (2006).
29. Persell SD, Baker DW. Studying interventions to prevent the progression from prehypertension to hypertension: does TROPHY win the prize? Am. J. Hypertens. 19(11), 1095-1097 (2006). (Pubitemid 44633603)
30. Meltzer JI. A specialist in clinical hypertension critiques the TROPHY trial. Am. J. Hypertens. 19(11), 1098-1100 (2006). (Pubitemid 44633604)
31. Lüders S, Schrader J, Berger J et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J. Hypertens. 26(7), 1487-1496 (2008).
32. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292(18), 2217-2225 (2004).
33. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (9287), 1033-1041 (2001).
34. Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J. Am. Coll. Cardiol. 48(4), 833-838 (2006). (Pubitemid 44175741)
35. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-ana lysis. JAMA 305(9), 913-922 (2011).
36. Ventura HO, Lavie CJ. Antihypertensive therapy for prehypertension: relationship with cardiovascular outcomes. JAMA 305(9), 940-941 (2011).
37. Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientifc statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115(21), 2761-2788 (2007). (Pubitemid 46842793)
38. Cruickshank JM, Thorp JM, Zacharias FJ. Benefts and potential of lowering high blood pressure. Lancet 1(8533), 581-584 (1987).
39. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 351(9118), 1755-1762 (1998). (Pubitemid 28269185)
40. Somes GW, Pahor M, Shorr RI et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch. Intern. Med. 159(17), 2004-2009 (1999). (Pubitemid 29453587)
41. Messerli FH, Mancia G, Conti R et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann. Intern. Med. 144(12), 884-893 (2006). (Pubitemid 46768128)
42. Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1575-1585 (2010).
43. Nilsson PM. ACCORD and risk factor control in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1628-1630 (2010).
44. Weber M. How far to reduce blood pressure in patients with diabetes-even after ACCORD, questions remain. J. Clin. Hypertens. 12(5), 321-322 (2010).
45. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with Type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 123(24), 2799-2810 (2011).
46. Fuchs FD, Fuchs SC, Moreira LB et al. Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. Trials 12, 65 (2011).